During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan ...

Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into ...

For Heart Health Month, Amy Ahnert, MD, discussed the link between cardiovascular disease and breast cancer.

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...